EBViNT Cell (Eutilex)

N/A

Report date: 2024/07/24 14:19:12

Base Information

Drug NameEBViNT Cell (Eutilex)

Drug Alias NameEpstein-Barr virus induced adoptive T-cell therapy - Eutilex

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Virus-specific T Cell therapyCell and gene therapy > Cell therapy > Source of cells > Blood-derived

Mechanisms of ActionCluster of differentiation 8 stimulants

TargetsCluster of differentiation 8

Therapy Area/IndicationsLymphoma, Extranodal NK-T-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySouth Korea

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesEutilex

China Registration ClassN/A

Develop Information

Active CompaniesEutilex

Inactive CompaniesN/A

Active IndicationsLymphoma, Extranodal NK-T-Cell

Inactive IndicationsN/A

Other Information

ATC CodeN/A